Northwest Biotherapeutics (NWBO) Income towards Parent Company (2010 - 2026)

Northwest Biotherapeutics' Income towards Parent Company history runs 17 years deep, the most recent figure standing at -$13.2 million for Q1 2026.

• On a quarterly basis, Income towards Parent Company rose 29.96% year-over-year to -$13.2 million in Q1 2026; TTM through Mar 2026 was -$71.1 million, a 12.47% increase from a year earlier, with the FY2025 full-year figure at -$60.7 million, up 27.55% from the prior year.
• Income towards Parent Company grew to -$13.2 million in Q1 2026 per NWBO's latest filing, from -$16.1 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$12.0 million in Q4 2023 and bottomed at -$130.2 million in Q3 2022.
• The 5-year median for Income towards Parent Company is -$16.9 million (2025), against an average of -$24.3 million.
• Across the five-year window, Income towards Parent Company sank 1017.61% in 2022 and surged 88.08% in 2023, its largest moves.
• Year by year, Income towards Parent Company stood at -$19.4 million in 2022, then surged by 38.35% to -$12.0 million in 2023, then sank by 118.81% to -$26.2 million in 2024, then surged by 38.52% to -$16.1 million in 2025, then increased by 17.86% to -$13.2 million in 2026.
• Per Business Quant, the three latest NWBO Income towards Parent Company figures stand at -$13.2 million (Q1 2026), -$16.1 million (Q4 2025), and -$16.9 million (Q3 2025).